EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY 4.0

Low-Dose vs Conventional-Dose Trimethoprim-Sulfamethoxazole Treatment for Pneumocystis Pneumonia in Patients Not Infected With HIV

Tatsuya Nagai, Hiroki Matsui, Haruka Fujioka, Yuya Homma, Ayumu Otsuki, Hiroyuki Ito, Shinichiro Ohmura, Toshiaki Miyamoto, Daisuke Shichi, Watari Tomohisa, Yoshihito Otsuka, Kei Nakashima

CHEST · 2024-01 · 165 (1) · 58-67

DOI: 10.1016/j.chest.2023.08.009 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift CHEST, 2024-01. Verfasst von Tatsuya Nagai und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonology, Kameda Medical Center, Kamogawa, Chiba, Japan. Hauptthemen laut MEDLINE: Pneumonia, Pneumocystis, HIV Infections. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Trimethoprim-sulfamethoxazole (TMP-SMX) is an effective treatment for Pneumocystis jirovecii pneumonia (PCP) in immunocompromised patients with and without HIV infection; however, a high incidence of adverse events has been observed. Low-dose TMP-SMX is a potentially effective treatment with fewer adverse events; however, evidence is limited. RESEARCH QUESTION: What is the efficacy and safety of low-dose TMP-SMX for non-HIV PCP compared with conventional-dose TMP-SMX after adjusting for patient background characteristics? STUDY DESIGN AND METHODS: In this multicenter retrospective cohort study, we included patients diagnosed with non-HIV PCP and treated with TMP-SMX between June 2006 and March 2021 at three institutions. The patients were classified into low-dose (TMP < 12.5 mg/kg/d) and conventional-dose (TMP 12.5-20 mg/kg/d) groups. The primary end point was 30-day mortality, and the secondary end points were 180-day mortality, adverse events grade 3 or higher per the Common Terminology Criteria for Adverse Events v5.0, and initial treatment completion rates. Background characteristics were adjusted using the overlap weighting method with propensity scores. RESULTS: Fifty-five patients in the low-dose group and 81 in the conventional-dose group were evaluated. In the overall cohort, the average age was 70.7 years, and the proportion of women was 55.1%. The average dose of TMP-SMX was 8.71 mg/kg/d in the low-dose group and 17.78 mg/kg/d in the conventional-dose group. There was no significant difference in 30-day mortality (6.7% vs 18.4%, respectively; P = .080) or 180-day mortality (14.6% vs 26.1%, respectively; P = .141) after adjusting for patient background characteristics. The incidence of adverse events, especially nausea and hyponatremia, was significantly lower in the low-dose group (29.8% vs 59.0%, respectively; P = .005). The initial treatment completion rates were 43.3% and 29.6% in the low-dose and conventional-dose groups (P = .158), respectively. INTERPRETATION: Survival was similar between the low-dose and conventional-dose TMP-SMX groups, and low-dose TMP-SMX was associated with reduced adverse events in patients with non-HIV PCP.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pneumonia, PneumocystisHIV InfectionsHumansFemaleAgedTrimethoprim, Sulfamethoxazole Drug CombinationRetrospective StudiesTreatment Outcome

Stichwörter der Autor:innen

immunocompromised patientslow-dose trimethoprim-sulfamethoxazolenon-HIV-infected patientspneumocystis pneumoniatreatment

Substanzen

Trimethoprim, Sulfamethoxazole Drug Combination

Autor:innen und Institutionen

  • Department of Pulmonology, Kameda Medical Center, Kamogawa, Chiba, Japan.
  • Department of Clinical Epidemiology and Health Economics, School of Public Health, University of Tokyo, Tokyo, Japan; Clinical Research Support Office, Kameda Medical Center, Kamogawa, Chiba, Japan.
  • Department of Rheumatology, Seirei Hamamatsu General Hospital, Hamamatsu, Shizuoka, Japan.
  • Department of Infectious Diseases and Rheumatology, Seirei Mikatahara General Hospital, Hamamatsu, Shizuoka, Japan.
  • Department of Laboratory Medicine, Kameda Medical Center, Kamogawa, Chiba, Japan.
  • Department of Pulmonology, Kameda Medical Center, Kamogawa, Chiba, Japan. Electronic address: kei.7.nakashima@gmail.com.

Zitieren

APA

Nagai, T., Matsui, H., Fujioka, H., Homma, Y., Otsuki, A., Ito, H., Ohmura, S., Miyamoto, T., Shichi, D., Tomohisa, W., Otsuka, Y., & Nakashima, K. (2024). Low-Dose vs Conventional-Dose Trimethoprim-Sulfamethoxazole Treatment for Pneumocystis Pneumonia in Patients Not Infected With HIV. CHEST, 165(1), 58-67. https://doi.org/10.1016/j.chest.2023.08.009

Vancouver

Nagai T, Matsui H, Fujioka H, Homma Y, Otsuki A, Ito H, et al. Low-Dose vs Conventional-Dose Trimethoprim-Sulfamethoxazole Treatment for Pneumocystis Pneumonia in Patients Not Infected With HIV. CHEST. 2024;165(1):58-67. doi:10.1016/j.chest.2023.08.009

BibTeX
@article{Nagai2024,
  author = {Nagai, Tatsuya and Matsui, Hiroki and Fujioka, Haruka and Homma, Yuya and Otsuki, Ayumu and Ito, Hiroyuki and Ohmura, Shinichiro and Miyamoto, Toshiaki and Shichi, Daisuke and Tomohisa, Watari and Otsuka, Yoshihito and Nakashima, Kei},
  title = {Low-Dose vs Conventional-Dose Trimethoprim-Sulfamethoxazole Treatment for Pneumocystis Pneumonia in Patients Not Infected With HIV},
  journal = {CHEST},
  year = {2024},
  volume = {165},
  number = {1},
  pages = {58--67},
  doi = {10.1016/j.chest.2023.08.009}
}
Kostenlos starten →